← RemeGen Co. Ltd. A overview

RemeGen Co. Ltd. A vs Amgen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

RemeGen Co. Ltd. A (688331.CG)

Q3 2026
▲4

RemeGen Surges on Profit Turnaround, Essential Drug Listing, Buyback

  • Drugs Added to National Essential Medicines List RemeGen's drugs joined China's 2026 National Essential Medicines List, which should boost sales and patient reach. This is a key regulatory win that supports future revenue growth.

    This is a new positive development that directly affects RemeGen's product demand and market access.

  • First-Half Profit Turnaround on 433% Revenue Surge RemeGen reported first-half net profit of 4.662 billion yuan, reversing a loss, driven by a 433% revenue surge. Licensing revenue from AbbVie contributed significantly to this turnaround.

    This is a major new financial result that shows a dramatic improvement in profitability, directly impacting investor sentiment.

  • Share Buyback Signals Management Confidence A 25–50 million yuan share buyback was announced, signaling management's confidence in the company's prospects. While relatively small, it supports the stock price.

    This is a new capital action that indicates insider confidence and can positively influence investor perception.

  • Sector Momentum Lifts Innovative Drug Stocks Sector-wide momentum and strong peer results lifted innovative drug stocks, including RemeGen. This positive sentiment provided an additional tailwind for the share price.

    This is a new external factor that contributed to RemeGen's stock performance during the quarter.

August 2026
▲4

RemeGen swings to profit on 433% revenue surge and buyback plan

  • Buyback plan supports shareholder value RemeGen's board approved a share buyback of 25–50 million yuan for employee incentives, using its own funds. This signals confidence and can support the stock price by reducing shares outstanding and showing management believes the stock is undervalued.

    This is a new capital action that directly affects the share price by signaling confidence and potentially boosting demand.

  • Interim profit forecast: 4.7 billion yuan swing to profit RemeGen expects first-half net profit of about 4.7 billion yuan, reversing a year-ago loss, driven by strong sales of core drugs and licensing revenue from AbbVie. This huge turnaround boosts investor confidence and earnings expectations.

    This is a major positive earnings surprise that directly improves the company's financial health and outlook.

  • Sector-wide rally lifts innovative drug stocks The pharmaceutical sector has been rising, with many stocks hitting daily limits, partly due to strong results from peers like WuXi AppTec and BeiGene. This positive sentiment can lift RemeGen's shares as part of the sector momentum.

    Sector momentum can drive demand for RemeGen shares even if company-specific news is already known.

  • Final half-year results confirm strong turnaround RemeGen reported actual first-half net profit of 4.662 billion yuan and revenue up 433%, matching its forecast. The official numbers confirm the turnaround, reinforcing the positive fundamental story and supporting the stock price.

    The official results validate the earlier forecast, removing uncertainty and solidifying the positive outlook.

Latest
▲4

RemeGen swings to profit on 433% revenue surge and buyback plan

  • Buyback plan supports shareholder value RemeGen's board approved a share buyback of 25–50 million yuan for employee incentives, using its own funds. This signals confidence and can support the stock price by reducing shares outstanding and showing management believes the stock is undervalued.

    This is a new capital action that directly affects the share price by signaling confidence and potentially boosting demand.

  • Interim profit forecast: 4.7 billion yuan swing to profit RemeGen expects first-half net profit of about 4.7 billion yuan, reversing a year-ago loss, driven by strong sales of core drugs and licensing revenue from AbbVie. This huge turnaround boosts investor confidence and earnings expectations.

    This is a major positive earnings surprise that directly improves the company's financial health and outlook.

  • Sector-wide rally lifts innovative drug stocks The pharmaceutical sector has been rising, with many stocks hitting daily limits, partly due to strong results from peers like WuXi AppTec and BeiGene. This positive sentiment can lift RemeGen's shares as part of the sector momentum.

    Sector momentum can drive demand for RemeGen shares even if company-specific news is already known.

  • Final half-year results confirm strong turnaround RemeGen reported actual first-half net profit of 4.662 billion yuan and revenue up 433%, matching its forecast. The official numbers confirm the turnaround, reinforcing the positive fundamental story and supporting the stock price.

    The official results validate the earlier forecast, removing uncertainty and solidifying the positive outlook.

July 2026
▲4

RemeGen's profit turnaround and new drug list inclusion drive gains

  • Essential medicines list inclusion RemeGen's innovative drugs were added to China's 2026 National Essential Medicines List, which should boost sales volume and long-term standardized treatment. This expands the patient base and supports revenue growth.

    This is a new regulatory catalyst that directly increases demand for RemeGen's products.

  • Share buyback plan RemeGen announced a 25-50 million yuan share buyback, part of a broader wave of central enterprise buybacks. This signals management confidence and can support the stock price by reducing shares outstanding.

    It shows insider confidence and provides a capital market support mechanism.

  • Profit turnaround expected RemeGen expects first-half 2026 net profit of about 4.7 billion yuan, swinging from a loss to a profit. This significant improvement reflects strong business performance and boosts investor confidence.

    It is a major financial milestone that directly impacts valuation and sentiment.

  • Sector momentum and licensing deals Innovative drug stocks rallied, with sector out-licensing deals reaching $99.7 billion in H1 2026. RemeGen's improved results were highlighted, drawing investor attention to the sector's growth potential.

    It shows broader industry tailwinds that can lift RemeGen's stock through increased sector investment.

▲4

RemeGen's profit turnaround and new drug list inclusion drive gains

  • Essential medicines list inclusion RemeGen's innovative drugs were added to China's 2026 National Essential Medicines List, which should boost sales volume and long-term standardized treatment. This expands the patient base and supports revenue growth.

    This is a new regulatory catalyst that directly increases demand for RemeGen's products.

  • Share buyback plan RemeGen announced a 25-50 million yuan share buyback, part of a broader wave of central enterprise buybacks. This signals management confidence and can support the stock price by reducing shares outstanding.

    It shows insider confidence and provides a capital market support mechanism.

  • Profit turnaround expected RemeGen expects first-half 2026 net profit of about 4.7 billion yuan, swinging from a loss to a profit. This significant improvement reflects strong business performance and boosts investor confidence.

    It is a major financial milestone that directly impacts valuation and sentiment.

  • Sector momentum and licensing deals Innovative drug stocks rallied, with sector out-licensing deals reaching $99.7 billion in H1 2026. RemeGen's improved results were highlighted, drawing investor attention to the sector's growth potential.

    It shows broader industry tailwinds that can lift RemeGen's stock through increased sector investment.

Amgen Inc (AMGN)

Q3 2026
▲3▼1

Amgen Q3: pipeline wins offset obesity and competition setbacks

  • Court blocks Colorado Enbrel price cap A court blocked Colorado's 70% price cap on Enbrel, protecting a key Amgen drug from a steep revenue cut. This legal win removes a major overhang and supports future sales.

    This is a new positive legal development that directly affects Amgen's revenue and stock sentiment.

  • Q2 earnings beat and raised guidance Amgen reported Q2 earnings per share of $6.29, beating expectations of about $5.60, and raised its full-year guidance. Growth products reached 70% of sales, showing the company's transition is working.

    This is a new positive financial update that exceeded expectations and boosted investor confidence.

  • Pipeline successes across multiple drugs Repatha cut mortality risk by 20%, Tezspire and dazodalibep showed positive results, and IMDELLTRA delivered landmark lung-cancer survival benefit with easier FDA monitoring. These advances strengthen Amgen's future revenue prospects.

    These are new clinical and regulatory wins that could drive future growth and lift earnings expectations.

  • Obesity hopes fade and competition rises Amgen discontinued its obesity drug AMG 513, and Novartis' pelacarsen failure cast doubt on Amgen's olpasiran, sinking shares about 10% and prompting a BMO downgrade. Meanwhile, Merck's cheaper oral PCSK9 and BMS's Sotyktu threaten Repatha and Otezla.

    This is a new negative development that hurt investor sentiment and the stock price, representing a key setback.

August 2026
▲3▼1

Amgen Q2 Beat and Pipeline Wins Lift Stock, But Risks Linger

  • Q2 earnings beat and raised guidance Amgen's Q2 2026 earnings beat expectations (EPS $6.29 vs. ~$5.60) and management raised full-year guidance, prompting analysts to lift price targets to $420–$460. This shows the company is performing better than expected and boosts investor confidence.

    This is the primary new event that drove the stock higher during the period.

  • Growth products now 70% of sales Repatha, Evenity, Uplizna, and Imdelltra grew 26% and now make up about 70% of Amgen's sales, reducing reliance on older drugs. This shift makes future revenue more stable and less exposed to patent cliffs.

    It highlights a fundamental improvement in Amgen's business mix that supports the stock.

  • Pipeline successes and cash from sale-leaseback Repatha cut death risk 20% in a major heart trial, Tezspire succeeded in eosinophilic esophagitis, and dazodalibep hit its Phase 3 goal in Sjögren's. A $151M Deerfield sale-leaseback added cash. These advances strengthen future growth prospects.

    These are new positive developments that could drive future revenue and cash flow.

  • Cyberattack, obesity setback, and drug-price risk A July cyberattack exposed patient data and triggered a class action investigation. Obesity hopes weakened after AMG 513 was discontinued, leaving MariTide trailing Lilly and Novo. A potential US drug-price agreement could pressure Medicaid revenue.

    These are new negative factors that could weigh on the stock and offset positive news.

Latest
▲4

Amgen Beats Q2, Wins Sjögren's Data, Sells Deerfield Campus

  • Q2 earnings beat lifts Amgen shares Amgen reported adjusted Q2 earnings of $6.29 per share, beating the $5.60 estimate, and shares rose 4.6%. Revenue also beat, showing the core business is growing faster than expected. This supports the stock because profits are the main driver of long-term value.

    The Q2 earnings beat is the period's biggest positive fundamental event and directly explains why AMGN moved up.

  • Positive Phase 3 data for dazodalibep in Sjögren's Amgen's dazodalibep met its main goal in a Phase 3 trial for systemic Sjögren's disease, a condition with no approved disease-modifying therapies. Success here adds a potential first-in-class drug to Amgen's pipeline, which can boost future sales and investor confidence.

    This is a new pipeline win that adds a future growth driver and supports the bull case for AMGN.

  • Deerfield campus sale-leaseback raises $151M cash Amgen sold its Deerfield office campus for $151 million and signed a long-term lease to stay in one building. This turns an illiquid property into cash without issuing shares or new debt, helping reduce the debt load from the Horizon acquisition. Shares rose 2.11% on the news.

    The sale-leaseback is a new capital move that improves Amgen's balance sheet and directly lifted the stock.

  • Analyst price targets raised on strong portfolio and Q2 beat Several banks including UBS, Argus, TD Cowen, Scotiabank and Oppenheimer raised Amgen price targets to $420–$460, citing a strong product portfolio, Q2 beats and higher guidance. Higher targets signal analysts see more upside, which can pull the stock up.

    The wave of target increases reflects improved analyst sentiment and is a key reason AMGN shares moved higher this period.

September 2026
▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

  • Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.

    This is the main new force driving AMGN down this period.

  • BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.

    Analyst downgrade is a direct new negative catalyst for the stock.

  • IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.

    A major positive pipeline win that offsets some of the Lp(a) pessimism.

  • FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.

    Regulatory win that improves commercial practicality of a growth drug.

▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

  • Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.

    This is the main new force driving AMGN down this period.

  • BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.

    Analyst downgrade is a direct new negative catalyst for the stock.

  • IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.

    A major positive pipeline win that offsets some of the Lp(a) pessimism.

  • FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.

    Regulatory win that improves commercial practicality of a growth drug.

▲3▼1

Amgen Hits 52-Week High on Q2 Beat, Repatha and Tezspire Wins

  • Repatha Cuts Death Risk 20% in Major Heart Trial Amgen's Repatha reduced death risk by 20% in high-risk heart patients in the VESALIUS-CV trial, a major win for its biggest growth drug. This strengthens the case for wider use and future sales, supporting a higher stock price.

    This is a new, high-impact clinical win that directly boosts confidence in Amgen's key growth driver.

  • Tezspire Meets All Goals in Eosinophilic Esophagitis Trial Amgen and AstraZeneca's Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, a chronic throat condition with few good treatments. This opens a new market and adds to Tezspire's growth story, lifting investor optimism.

    New positive trial results expand a key product's potential, a fresh catalyst for the stock.

  • US Drug Price Agreement with Mid-Sized Biotechs Looms The Trump administration is expected to announce a drug price agreement with mid-sized biotech firms, and Amgen was among companies urged to cut US prices. If Amgen is included, lower Medicaid prices could pressure revenue and weigh on the stock.

    This is a new regulatory risk that could directly affect Amgen's pricing and profits.

  • Analyst Fair Value and Price Targets Raised After Q2 Beat Following Amgen's strong Q2 results, analysts raised their fair value estimate to about $372 and several price targets into the $450 range, citing broad franchise strength. Higher targets can pull the stock up as investors adjust expectations.

    This is a new analyst reaction that reflects upgraded expectations and can influence the stock price.

▲2▼2

Amgen Q2 Beat and Guidance Raise Outweigh Data Breach and Obesity Setback

  • Q2 earnings beat and raised 2026 guidance Amgen reported Q2 adjusted EPS of $6.29, well above the $5.62 consensus, and revenue of $10.05 billion, up 10% and ahead of forecasts. Management raised full-year revenue and EPS guidance, signaling confidence in the business. This directly boosts the stock as investors see stronger profits ahead.

    This is the main new positive event that drove the stock up over 5% this period.

  • Key growth drivers show strong momentum Six key products, including Repatha, Evenity, Uplizna, and Imdelltra, grew 26% year-over-year and now make up nearly 70% of product sales. This reduces reliance on older drugs like Enbrel and Otezla, which are facing competition. The shift supports future revenue growth and lifts investor confidence.

    It explains the underlying strength behind the earnings beat and why the stock rose.

  • Cybersecurity breach and class action investigation Amgen disclosed a July cyberattack where sensitive patient and proprietary data was stolen. A law firm has launched a class action investigation. This creates legal and reputational risk, which could weigh on the stock, though Amgen says operations are not materially affected.

    It is a new negative event that could pressure the stock and is important for a balanced view.

  • Obesity drug AMG 513 discontinued; MariTide faces tough competition Amgen ended development of early-stage obesity drug AMG 513, leaving MariTide as its only obesity candidate. MariTide's weight-loss data trails Eli Lilly's and Novo Nordisk's drugs, and switching patients may be hard. This raises doubts about Amgen's ability to compete in the lucrative obesity market.

    It is a new setback that could limit future growth and is a key counterweight to the positive earnings.

July 2026
▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

  • Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.

    This is a major new legal win that directly supports Amgen's revenue outlook.

  • Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.

    New recalls create fresh regulatory and reputational risk that can hurt the stock.

  • New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.

    A new lower-priced competitor directly challenges a key Amgen growth drug.

  • Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.

    New competitive data shows a direct threat to an existing Amgen product.

▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

  • Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.

    This is a major new legal win that directly supports Amgen's revenue outlook.

  • Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.

    New recalls create fresh regulatory and reputational risk that can hurt the stock.

  • New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.

    A new lower-priced competitor directly challenges a key Amgen growth drug.

  • Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.

    New competitive data shows a direct threat to an existing Amgen product.

Q2 2026
▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

June 2026
▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.